Halberd

Halberd Financing Cash Flow

The Net Financing Cash Flow of Halberd (HALB) as of Oct 10, 2026 is 50,000.00 USD. In the previous year, Net Financing Cash Flow was 238,120.00 USD — a change of -79.00% (lower).

Financing Cash Flow

50,000.00USD

YoY

-79.00%

Last updated:

Net Financing Cash Flow of Halberd is 2024 50,000.00 USD. Net Financing Cash Flow of Halberd was 2023 238,120.00 USD. It decreases by -79.00% lower compared to the previous year.

The Halberd Financing Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financing Cash Flow
Date
Financing Cash Flow
Jan 1, 2020
44,650.00 USD
Jan 1, 2021
809,815.00 USD
Jan 1, 2022
893,400.00 USD
Jan 1, 2023
238,120.00 USD
Jan 1, 2024
50,000.00 USD
The Halberd Financing Cash Flow history
YEARFinancing Cash FlowYoY
50,000.00USD-79.00%
238,120.00USD-73.35%
893,400.00USD+10.32%
809,815.00USD+1,713.70%
44,650.00USD—
Access this data via the Eulerpool API

Halberd Stock analysis

What does Halberd do? The Halberd Corp is an American company founded in 1987 and based in New York. It is a high-tech company focused on the development of medical technologies. Since its inception, the company has developed numerous innovative products and technologies that are used worldwide. A significant portion of Halberd Corp's business model focuses on providing medical products and solutions for various diseases. The main divisions of the company are biotechnology and pharmaceuticals, medical respiratory protection, medical technology, and the development of antibodies and diagnostics. Some of the most well-known products of Halberd Corp are the Medical Respiratory Masks, which were of great importance during the COVID-19 pandemic. These masks were developed and distributed worldwide by the company with innovative technology and the highest quality standards. The company has also developed various medical devices such as infusion pumps, blood pressure monitors, and various diagnostic devices that have been used by hospitals and care facilities. Another important business area of Halberd Corp is biotechnology and pharmaceuticals. In this field, the company specializes in developing new drugs and therapies for various diseases. The company has developed a range of proprietary medications that are used in the treatment of various diseases. Halberd Corp is also known for its development of antibodies and diagnostics and offers corresponding test kits. In recent years, Halberd Corp has formed numerous partnerships with other companies and institutions to bring its innovations to the market and market them. The company is also known for its successful joint ventures with other companies in the healthcare sector. Overall, Halberd Corp is an innovative company focused on medical technologies. With its presence in various areas of the healthcare industry, the company is able to develop new products and solutions that have the potential to improve and save lives. Halberd is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Halberd stock

Net Financing Cash Flow of Halberd is 50,000.00 USD in 2024.

Net Financing Cash Flow of Halberd changed from 238,120.00 USD to 50,000.00 USD, representing a -79.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Financing Cash Flow Halberd since 2006 – with annual values, charts, and detailed analysis.

Financing cash flow measures cash flows from debt issuance/repayment, equity transactions, and dividend payments.

Net Financing Cash Flow's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Financing Cash Flow's Halberd historically and in real time.

Access this data via the Eulerpool API

Cash Flow — Halberd

All Key Metrics — Halberd